{"id":"14c-biib061","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T05:48:10.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123331,"model":"claude-sonnet-4-5-20250929"},"description":"14C-BIIB061 is a radiolabeled investigational compound developed by Biogen currently in Phase 1 clinical trials. The radiolabeled carbon-14 isotope suggests this formulation is being used for pharmacokinetic and metabolism studies to track drug distribution and elimination in the body.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Adult volunteers"}]},"trialDetails":[{"nctId":"NCT02071121","phase":"PHASE1","title":"Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-12","conditions":"Healthy","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"14C-BIIB061","genericName":"14C-BIIB061","companyName":"Biogen","companyId":"biogen","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}